Suppr超能文献

PowerPICC 导管及其附件的性能和安全性:一项前瞻性观察研究。

Performance and safety of PowerPICC catheters and accessories: a prospective observational study.

机构信息

University Hospital Olomouc, Olomouc, Czech Republic.

Bolzano Central Hospital, Bolzano, Italy.

出版信息

BMJ Open. 2024 Sep 30;14(9):e081288. doi: 10.1136/bmjopen-2023-081288.

Abstract

OBJECTIVE

This study aimed to evaluate the safety and performance of PowerPICC catheters in a real-world setting.

DESIGN

Prospective, observational, multicentre study.

SETTING

Nine European countries, involving 14 centres.

PARTICIPANTS

General patient population.

INTERVENTION

PowerPICC catheter inserted by the clinician as standard of care with routinely collected outcomes followed through device removal or 180 days postinsertion.

PRIMARY AND SECONDARY OUTCOMES MEASURES

Safety and performance outcomes were assessed for PowerPICC, PowerPICC SOLO 2 and PowerGroshong PICC. The primary safety endpoint was the incidence of symptomatic venous thrombosis (VT), and secondary safety endpoints included phlebitis, extravasation, vessel laceration, vessel perforation local infection, accidental dislodgment and catheter-related bloodstream infection (CRBSI). The primary performance endpoint was the percentage of patients whose PowerPICC device remained in place through the completion of therapy. The secondary performance endpoints included catheter patency, placement success in a single attempt and usability.

RESULTS

The enrolled patients (N=451) received either PowerPICC, PowerPICC SOLO 2 or PowerGroshong PICC catheters. Across all devices, 1.6% of patients developed symptomatic VT, and CRBSI occurred in 1.6% of patients. There were no cases of phlebitis or extravasation and only three cases of vein laceration or vein perforation. The catheters showed high success rates in completing therapy (81.8%), maintaining patency (93.9%) and achieving successful placement in a single attempt (90.4%). Clinicians overwhelmingly agreed that both the guidewire and stylet (93.3% and 94.4%, respectively) were easy or very easy to use.

CONCLUSIONS

This study demonstrates the safety and performance of PowerPICC catheters across diverse settings and patient cohorts in real-world hospital settings across Europe. The findings indicate that these catheters are safe and can be effectively used in the general patient setting and when inserted by a variety of clinicians. The low incidence of complications and high success rates further support the clinical utility of these catheters.

TRIAL REGISTRATION NUMBER

NCT04263649.

摘要

目的

本研究旨在评估 PowerPICC 导管在真实环境中的安全性和性能。

设计

前瞻性、观察性、多中心研究。

地点

九个欧洲国家,涉及 14 个中心。

参与者

一般患者人群。

干预措施

PowerPICC 导管由临床医生作为标准护理插入,通过设备移除或插入后 180 天跟踪常规收集结果。

主要和次要结果测量

评估 PowerPICC、PowerPICC SOLO 2 和 PowerGroshong PICC 的安全性和性能结果。主要安全性终点是症状性静脉血栓形成(VT)的发生率,次要安全性终点包括静脉炎、外渗、血管撕裂、血管穿孔、局部感染、意外移位和导管相关血流感染(CRBSI)。主要性能终点是完成治疗的患者中 PowerPICC 设备仍在位的百分比。次要性能终点包括导管通畅性、单次尝试中的放置成功率和可用性。

结果

纳入的患者(N=451)接受了 PowerPICC、PowerPICC SOLO 2 或 PowerGroshong PICC 导管。所有设备中,1.6%的患者发生症状性 VT,1.6%的患者发生 CRBSI。无静脉炎或外渗病例,仅有 3 例血管撕裂或穿孔病例。导管在完成治疗(81.8%)、保持通畅(93.9%)和单次尝试中成功放置(90.4%)方面显示出高成功率。临床医生非常同意导丝和引导针(分别为 93.3%和 94.4%)易于或非常易于使用。

结论

本研究在欧洲不同医院的真实环境中,展示了 PowerPICC 导管在不同环境和患者群体中的安全性和性能。研究结果表明,这些导管是安全的,可以在普通患者环境中有效使用,并且可以由各种临床医生插入。并发症发生率低和成功率高进一步支持了这些导管的临床实用性。

临床试验注册号

NCT04263649。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73ed/11448161/1c50e8bdcc90/bmjopen-14-9-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验